---
title: US drug shortages push CDMO outsourcing to Europe in 2026
slug: us-drug-shortages-push-cdmo-outsourcing-to-europe-in-2026-cdmo
site: cdmo
post_kind: deep_dive
byline: Carlton Hoyt
description: A tidy story is circulating: US drug shortages are pushing sponsors toward European CDMOs. The deal data supports half of it. Sponsors are moving manufacturing of newly approved drugs to Europe, and…
canonical_url: https://www.cdmo.directory/posts/us-drug-shortages-push-cdmo-outsourcing-to-europe-in-2026-cdmo
published_at: 2026-11-19T05:01:17.495Z
last_updated: 2026-11-19T05:01:18.905Z
---

A tidy story is circulating: US drug shortages are pushing sponsors toward European CDMOs. The deal data supports half of it. Sponsors are moving manufacturing of newly approved drugs to Europe, and they are doing it despite tariffs. The evidence does not show that shortages are the cause, and the two stories involve different parts of the market. A CDMO buyer who merges them will end up asking the wrong questions in the next RFP.

This essay separates the two and then looks at what each one means for a shortlist.

## What the 2025 deal data shows

GlobalData's deal tracking, as reported by [Pharma Manufacturing](https://www.pharmamanufacturing.com/sector/contract-manufacturing/article/55388759/outsourcing-of-new-drug-manufacturing-continues-to-shift-to-europe-globaldata), found that US contract manufacturing deals for FDA-approved drugs [fell more in 2025 than](https://www.pharmamanufacturing.com/sector/contract-manufacturing/article/55388759/outsourcing-of-new-drug-manufacturing-continues-to-shift-to-europe-globaldata) in any of the previous five years. The gap between US-based and Europe-based deals was the widest yet. [Pharmaceutical Technology](https://www.pharmaceutical-technology.com/analyst-comment/fda-approved-drug-manufacturing-deals-shifting-europe/) adds the detail that matters most for buyers. This happened despite the highest import tariffs in modern history on EU pharmaceuticals. US-based biopharma companies were among those sending work to European sites for the US market rather than choosing domestic suppliers.

That result cuts against the assumption that tariff pressure automatically pulls work onshore. Sponsors appear to be weighing tariff exposure against other things: available capacity, technical fit, regulatory track record, and the pace at which a new approval has to be supplied. The sources do not explain why European sites are winning, so any single explanation would be speculation. They do show that when a sponsor picks a CDMO for a launch, a US address is not the deciding factor it once was assumed to be.

The scope of this data is narrow. It covers contract manufacture of newly approved drugs, the territory of GlobalData's [annual contract manufacture report](https://www.globaldata.com/store/report/new-drug-approvals-and-contract-manufacturing-industry-analysis/), which tracks which companies win outsourcing contracts for new approvals and how outsourcing strategies change over time. It does not measure legacy generics, sterile injectables, or the older products where shortages tend to appear. That distinction matters for the rest of this piece.

## Why shortages are a separate problem

Shortage lists are dominated by established products, not recent approvals. Launch-stage manufacturing decisions for new drugs and shortage response for old ones run on different economics, with different sponsors, different contract structures, and different failure modes. A new approval with a well-funded owner can absorb a European supply chain and its tariff cost. A low-margin generic injectable often cannot.

The domestic fallback is also thinner than the policy debate suggests. In an interview with [PharmExec](https://www.pharmexec.com/view/role-503b-outsourcing-compounding-actually-play-filling-supply-gaps), Marc Wagner describes 503A pharmacies and 503B outsourcing facilities as playing real roles in easing shortages. He also notes that most generic drug products are made outside the US, so these sites may not be able to fill the gap at scale. A [Pharmaceutical Commerce analysis](https://www.pharmaceuticalcommerce.com/view/have-503b-outsourcing-facilities-truly-reduced-us-drug-shortages-) reaches a cautious conclusion. Credible evidence shows a meaningful minority of outsourcing facilities do produce drugs on the FDA shortage list. That is not the same as showing that they have reduced shortages.

Congress is trying to change that economics. Rep. Buddy Carter's [Growing America's Pharmaceutical Supply Act](https://buddycarter.house.gov/news/documentsingle.aspx?DocumentID=16341) would give outsourcing facilities the certainty to invest in producing shortage medications. It is an introduced bill, not law, and the sources do not say whether it will advance. It is worth tracking as a signal of where domestic sterile capacity might be incentivized. It is not something to plan a supply chain around.

So the useful reading is that two things are happening at once. New-approval manufacturing is drifting toward Europe. Shortage mitigation for older products still depends on a supply base that is mostly offshore and, in the US, partly dependent on 503B capacity whose contribution is debated. Neither trend tells you that a US CDMO is the safe choice or that a European one is.

## The policy pressure that makes site geography a risk variable

Several developments in the evidence make where a product is made a bigger line item in supplier selection.

According to a [PharmaSource discussion with Gil Roth](https://pharmasource.global/content/podcast/2026-us-pharma-outsourcing-gil-roth-on-fda-cuts-pricing-pressures-and-cdmo-strategy/), the 2026 environment combines:

- FDA staff losses alongside promises to fast-track advanced modalities.
- The BIOSECURE Act, signed into law with five-year phase-out timelines.
- Tariffs that the discussion describes as creating cost increases of up to 50% on manufacturing.

The source excerpt is brief, so treat the 50% figure as a characterization from that conversation, not a measured industry average. Ask any vendor quoting a tariff-driven surcharge to show the arithmetic.

The enforcement side also matters. An [IntuitionLabs review of 2026 FDA enforcement data](https://intuitionlabs.ai/articles/contract-manufacturing-oversight-fda-enforcement-2026) describes a pivot toward aggressive enforcement of outsourcing controls, pointing to a sharp rise in warning letters and new supply-chain regulations. If that reading holds, responsibility for the CDMO's quality performance sits increasingly with the sponsor. Moving a product to a European site does not move the sponsor's oversight duties. It may add distance to them.

The pieces fit together uncomfortably. FDA capacity is described as strained, which raises questions about inspection timing and review predictability. BIOSECURE adds a compliance dimension to supplier ownership and supply chain. Tariffs raise the price of crossing the Atlantic. Yet the deal data shows sponsors crossing it anyway. That suggests the European sites on offer are solving a problem that the tariff arithmetic alone does not capture, whether capacity, timing, or technical capability.

## How a shortlist changes

A few practical shifts follow, with the caveat that the evidence is aggregate and your product may not behave like the average.

**Europe belongs on the first-round list for new launches.** If your drug is newly approved or near approval, a shortlist limited to US sites is now unrepresentative of where peers are placing work. Include European CDMOs from the start, and price tariff exposure explicitly rather than treating it as disqualifying.

**For established or shortage-prone products, geography is not the main question.** Redundancy is. A single-site arrangement, domestic or European, is a shortage risk. The more useful comparison is between a vendor that can show a qualified second site and one that cannot.

**A CDMO's location does not substitute for oversight evidence.** With enforcement described as intensifying, a vendor's inspection history, corrective action closure, and quality agreement discipline deserve at least as much weight as its country of operation.

**Domestic 503B capacity is a niche tool, not a backstop.** If your product is a sterile injectable on or near the shortage list, a 503B facility may be part of a contingency conversation. The evidence stops well short of showing it can replace a primary manufacturing site.

## Questions worth putting in the next RFP

These are framed to separate vendors with real answers from those with sales positions.

1. **Where will the drug substance, drug product, and packaging each be made?** Tariff and BIOSECURE exposure can sit at any step, not only the final site.
2. **Who bears tariff cost, and under what trigger?** Ask for the pricing clause, not a verbal assurance, given how volatile the 2026 tariff picture is.
3. **What is your second-site plan, and what is its qualification timeline?** A plan on paper and a qualified site are different things.
4. **How do you handle ownership and supply-chain screening under BIOSECURE?** Look for specifics on subcontractors and raw material sources, not a statement that you are compliant.
5. **What is your recent inspection record, and how did you close observations?** Match this to the enforcement trend rather than to marketing claims.
6. **How would you respond to a shortage declaration on my product?** Ask for a concrete escalation path, including capacity reserved or available on short notice.
7. **If FDA timelines slip, how does that change your scheduling commitments?** Strained agency capacity is a scheduling risk you can partially contract around.

## What the evidence cannot tell you

The sources are a mix of deal-tracking analysis, trade commentary, a legislative announcement, and a podcast summary. None directly tests whether a shift to European CDMOs improves or worsens shortage outcomes. The GlobalData findings cover new approvals, not shortage-prone products. The 503B sources describe a contested contribution, not a measured one. The Carter bill is a proposal. The enforcement and tariff claims come from secondary summaries whose underlying data you should check before using in a business case.

What holds up is narrower and more useful. In 2025, the market voted with contracts for European manufacturing of US-bound new drugs, even at a tariff cost. Shortage response remains an offshore-heavy, thinly backed problem. And in 2026, the burden of showing that your supply chain is controlled falls more heavily on the sponsor. A CDMO shortlist built on those three facts will look different from one built on the idea that shortages are pulling everything toward Europe, or back to the US.

## Sources

1. New Drug Approvals and Their [Contract Manufacture: 2026 Edition (GlobalData)](https://www.globaldata.com/store/report/new-drug-approvals-and-contract-manufacturing-industry-analysis/)
2. Contract [Manufacturing Oversight: 2026 FDA Enforcement](https://intuitionlabs.ai/articles/contract-manufacturing-oversight-fda-enforcement-2026) Data (IntuitionLabs)
3. [Pharma Outsourcing 2026 Trends: FDA](https://pharmasource.global/content/podcast/2026-us-pharma-outsourcing-gil-roth-on-fda-cuts-pricing-pressures-and-cdmo-strategy/) Cuts, Pricing Pressures and CDMO Strategy (PharmaSource)
4. Carter [introduces bill incentivizing domestic production](https://buddycarter.house.gov/news/documentsingle.aspx?DocumentID=16341) to alleviate drug shortages (Rep. Buddy Carter)
5. In the face of [tariffs, FDA-approved drug manufacturing deals](https://www.pharmaceutical-technology.com/analyst-comment/fda-approved-drug-manufacturing-deals-shifting-europe/) are shifting to Europe (Pharmaceutical Technology)
6. Have [503B Outsourcing Facilities Truly Reduced](https://www.pharmaceuticalcommerce.com/view/have-503b-outsourcing-facilities-truly-reduced-us-drug-shortages-) US Drug Shortages? (Pharmaceutical Commerce)
7. The Role That 503B [Outsourcing and Compounding Pharmacies Actually](https://www.pharmexec.com/view/role-503b-outsourcing-compounding-actually-play-filling-supply-gaps) Play in Filling Supply Gaps (PharmExec)
8. Outsourcing of new drug manufacturing continues to shift [to Europe: GlobalData (Pharma Manufacturing)](https://www.pharmamanufacturing.com/sector/contract-manufacturing/article/55388759/outsourcing-of-new-drug-manufacturing-continues-to-shift-to-europe-globaldata)

Source: https://www.cdmo.directory/posts/us-drug-shortages-push-cdmo-outsourcing-to-europe-in-2026-cdmo